Literature DB >> 25539366

Choosing wisely? Patterns and correlates of the use of hypofractionated whole-breast radiation therapy in the state of Michigan.

Reshma Jagsi1, Kent A Griffith2, David Heimburger3, Eleanor M Walker4, Inga S Grills5, Thomas Boike6, Mary Feng2, Jean M Moran2, James Hayman2, Lori J Pierce2.   

Abstract

PURPOSE: Given evidence from randomized trials that have established the non-inferiority of more convenient and less costly courses of hypofractionated radiotherapy to the whole breast in selected breast cancer patients who receive lumpectomy, we sought to investigate the use of hypofractionated radiation therapy and factors associated with its use in a consortium of radiation oncology practices in Michigan. We sought to determine the extent to which variation in use occurs at the physician or practice level versus the extent to which use reflects individualization based on potentially relevant patient characteristics (such as habitus, age, chemotherapy receipt, or laterality). METHODS AND MATERIALS: We evaluated associations between receipt of hypofractionated radiation therapy and various patient, provider, and practice characteristics in a multilevel model.
RESULTS: Of 1477 patients who received lumpectomy and whole-breast radiation therapy and were registered by the Michigan Radiation Oncology Quality Consortium (MROQC) from October 2011 to December 2013, 913 had T1-2, N0 breast cancer. Of these 913, 283 (31%) received hypofractionated radiation therapy. Among the 13 practices, hypofractionated radiation therapy use ranged from 2% to 80%. On multilevel analysis, 51% of the variation in the rate of hypofractionation was attributable to the practice level, 21% to the provider level, and 28% to the patient level. On multivariable analysis, hypofractionation was more likely in patients who were older (odds ratio [OR] 2.16 for age ≥50 years, P=.007), less likely in those with larger body habitus (OR 0.52 if separation between tangent entry and exit ≥25 cm, P=.002), and more likely without chemotherapy receipt (OR 3.82, P<.001). Hypofractionation use was not higher in the last 6 months analyzed: 79 of 252 (31%) from June 2013 to December 2013 and 204 of 661 (31%) from October 2011 to May 2013 (P=.9).
CONCLUSIONS: Hypofractionated regimens of whole-breast radiation therapy have been variably administered in the adjuvant setting in Michigan after the publication of long-term trial results and consensus guidelines. Most of this variability is explained at the practice and provider level rather than by patient-level features, although care is being individualized to some degree.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25539366     DOI: 10.1016/j.ijrobp.2014.09.027

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

Review 1.  A scoping review characterizing "Choosing Wisely®" recommendations for breast cancer management.

Authors:  Hely Shah; Julian Surujballi; Arif Ali Awan; Brian Hutton; Angel Arnaout; Risa Shorr; Lisa Vandermeer; Mashari Jemaan Alzahrani; Mark Clemons
Journal:  Breast Cancer Res Treat       Date:  2020-11-06       Impact factor: 4.872

2.  Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer.

Authors:  Payal D Soni; Philip S Boonstra; Matthew J Schipper; Latifa Bazzi; Robert T Dess; Martha M Matuszak; Feng-Ming Kong; James A Hayman; Randall K Ten Haken; Theodore S Lawrence; Gregory P Kalemkerian; Shruti Jolly
Journal:  J Thorac Oncol       Date:  2017-02-01       Impact factor: 15.609

3.  Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial.

Authors:  Simona F Shaitelman; Pamela J Schlembach; Isidora Arzu; Matthew Ballo; Elizabeth S Bloom; Daniel Buchholz; Gregory M Chronowski; Tomas Dvorak; Emily Grade; Karen E Hoffman; Patrick Kelly; Michelle Ludwig; George H Perkins; Valerie Reed; Shalin Shah; Michael C Stauder; Eric A Strom; Welela Tereffe; Wendy A Woodward; Joe Ensor; Donald Baumann; Alastair M Thompson; Diana Amaya; Tanisha Davis; William Guerra; Lois Hamblin; Gabriel Hortobagyi; Kelly K Hunt; Thomas A Buchholz; Benjamin D Smith
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

4.  Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial.

Authors:  Simona F Shaitelman; Xiudong Lei; Alastair Thompson; Pamela Schlembach; Elizabeth S Bloom; Isidora Y Arzu; Daniel Buchholz; Gregory Chronowski; Tomas Dvorak; Emily Grade; Karen Hoffman; George Perkins; Valerie K Reed; Shalin J Shah; Michael C Stauder; Eric A Strom; Welela Tereffe; Wendy A Woodward; Diana N Amaya; Yu Shen; Gabriel N Hortobagyi; Kelly K Hunt; Thomas A Buchholz; Benjamin D Smith
Journal:  J Clin Oncol       Date:  2018-10-31       Impact factor: 44.544

5.  Characteristics of Physicians Participating in Medicare's Oncology Care Model Bundled Payment Program.

Authors:  Ravi B Parikh; Justin E Bekelman; Qian Huang; Joseph R Martinez; Ezekiel J Emanuel; Amol S Navathe
Journal:  J Oncol Pract       Date:  2019-08-08       Impact factor: 3.714

6.  Big Data in Designing Clinical Trials: Opportunities and Challenges.

Authors:  Charles S Mayo; Martha M Matuszak; Matthew J Schipper; Shruti Jolly; James A Hayman; Randall K Ten Haken
Journal:  Front Oncol       Date:  2017-08-31       Impact factor: 6.244

7.  Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely (®) Initiative.

Authors:  Jeffrey Landercasper; Lisa Bailey; Tiffany S Berry; Robert R Buras; Amy C Degnim; Oluwadamilola M Fayanju; Joshua Froman; Jennifer Gass; Caprice Greenberg; Starr Koslow Mautner; Helen Krontiras; Roshni Rao; Michelle Sowden; Judy A Tjoe; Barbara Wexelman; Lee Wilke; Steven L Chen
Journal:  Ann Surg Oncol       Date:  2016-06-22       Impact factor: 5.344

8.  Choosing wisely after publication of level I evidence in breast cancer radiotherapy.

Authors:  Joshua R Niska; Sameer R Keole; Barbara A Pockaj; Michele Y Halyard; Samir H Patel; Donald W Northfelt; Richard J Gray; Nabil Wasif; Carlos E Vargas; William W Wong
Journal:  Breast Cancer (Dove Med Press)       Date:  2018-02-09

9.  Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care?

Authors:  Diane C Ling; John A Vargo; Sushil Beriwal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-10-01       Impact factor: 7.038

10.  Implementation and utilization of hypofractionation for breast cancer.

Authors:  Philip Gilbo; Louis Potters; Lucille Lee
Journal:  Adv Radiat Oncol       Date:  2018-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.